Abstract:BACKGROUND:Acute complications, such as venous thromboembolism (VTE), are common in patients with advanced severe lung cancers. However, current VTE risk scores cannot adequately identify high-risk patients with non-small cell lung cancer (NSCLC). The study proposed to elucidated the incidence of thromboembolism (TE) in patients with different oncogenic aberrations and the impact of these aberrations on the efficacy of targeted therapy in patients with NSCLC.METHODS:A systemic review was conducted in Web of Science, PubMed, Embase and the Cochrane Library to evaluate the incidence of TE in different molecular subtypes of NSCLC. Data from patients diagnosed of advanced NSCLC who harboring anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements since 2016 to 2019 were also retrospectively collected. A meta-analysis with random-effects model, sensitivity analysis and publication bias were performed. The principal summary measure was incidence of thrombotic events in NSCLC patients. And the efficacy of tyrosine kinase inhibitor (TKI) therapy was compared between the two subgroups.RESULTS:A total of 5,767 cases from 20 studies were included in the analysis of the incidence of thrombosis in patients with different oncogenic alterations. The pooled analysis showed a higher risk of thrombosis in ROS1-fusion types (41%, 95% CI: 35-47%) and ALK-fusion types (30%, 95% CI: 24-37%) than in EGFR-mutation (12%, 95% CI: 8-17%), KRAS-mutation (25%, 95% CI: 13-50%), and wild-type (14%, 95% CI: 10-20%) cases. A high prevalence of thrombosis (ALK: 24.4%; ROS1: 32.6%) was observed in the Shanghai Pulmonary Hospital (SPH) cohort of 224 patients with ALK or ROS1 fusion. Furthermore, patients with embolism had significantly shorter progression-free survival (PFS) after TKI therapy than those without embolism, both in the ALK+ cohort (5.6 vs. 12.9 months, P<0.0001) and in the ROS1+ cohort (9.6 vs. 17.6 months, P=0.0481).CONCLUSIONS:NSCLC patients with ALK/ROS1 rearrangements are more likely to develop thrombosis than patients with other oncogenic alterations. Thrombosis may also be associated with an inferior response and PFS after TKI therapy.

A Novel Oncotherapy Strategy: Direct Thrombin Inhibitors Suppress Progression, Dissemination and Spontaneous Metastasis in Non‐small Cell Lung Cancer

High Discrepancy in Thrombotic Events in Non-Small Cell Lung Cancer Patients with Different Genomic Alterations

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer with Liver Metastases

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

[Minimally Invasive Therapies for Early Stage Non-small Cell Lung Cancer].

Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation

The Stimulatory Activity of Plasma in Patients with Advanced Non-Small Cell Lung Cancer Requires TLR-stimulating Nucleic Acid Immunoglobulin Complexes and Discriminates Responsiveness to Chemotherapy.

Novel therapeutic strategies for rare mutations in non-small cell lung cancer

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients with Early-Stage Non-small Cell Lung Cancer

[The conceptual oligometastatic non-small cell lung cancer and therapeutic strategies].

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy.

Circulating Tumor Cells Dynamics During Chemotherapy Predict Survival and Response in Advanced Non-Small-cell Lung Cancer Patients.

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Relationship between thrombocytosis and effect of chemotherapy, prognosis in patients with advanced non-small cell lung cancer

Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

LncRNAs in non-small cell lung cancer: novel diagnostic and prognostic biomarkers

Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors

Emerging therapies for non-small cell lung cancer

Abstract 5979: Evaluating therapeutic strategies against lung cancer using multispectral optoacoustic tomography